Greg Zante

Greg Zante

Chief Financial OfficeratViking Therapeutics· In proxies 2022–2025

Pay in FY2025+10% from the year before · Viking Therapeutics stock -12.6% the same year

Greg Zante was paid $5.1M in FY2025 (Dec), up 10%. Viking Therapeutics stock fell 12.6% that year.

Pay$100 in the stock at the end of FY21 → $765
Pay is from the Summary Compensation Table of each Viking Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Viking TherapeuticsPublic company · 4 yr
    • Chief Financial Officer2022 – Present · 4 yrStock in role +421%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?